Drugs Online |
 |
 | ||
|
Intalith CR Eskalith |
|
| ||
Drugs Online » Prescription Drugs 9 » Intalith CR Eskalith Indications1.Treatment of mania and hypomania. 2.Lithium may also be tried in the treatment of some patients with recurrent bipolar depression for which treatment with other antidepressants has been unsuccessful. 3.Prophylactic treatment of recurrent affective disorders.Dosage and AdministrationA simple treatment schedule has been evolved which except for some minor variations should be followed whether using LITHICARB FC therapeutically or prophylactically. The minor variations to this schedule depend on the elements of the illness being treated and these are described later.1. In patients of average weight (70kg) an initial dose of 400- 1 200mg of LITHICARB FC may be given as a single daily dose in the morning or on retiring. Alternatively the dose may be divided and given morning and evening. The tablets should not be crushed chewed or swallowed with hot liquids. When changing from other lithium preparations serum lithium levels should first be checked then 2. LITHICARB FC therapy commenced at a daily dose as close as possible to the dose of the other form of lithium. As bioavailability varies from product to product (particularly with regard to retard or slow release preparations) a change of product should be regarded as initiation of new treatment. 3. Four to five days after starting treatment (and never longer than one week) a blood sample should be taken for the estimation of serum lithium level. 4. The objective is to adjust the LITHICARB FC dose so as to maintain the serum lithium level permanently within the diurnal range of 0.5 - 1.5 mmol/L. In practice the blood sample should be taken between 12 and 24 hours after the previous dose of LITHICARB FC. 'Target' serum lithium concentrations at 12 and 24 hours are shown in Table 1.LITHICARB FC tablets are scored therefore they can be divided accurately to provide dosage adjustments as small as 125mg. Serum lithium levels should be monitored weekly until stabilisation is achieved.Table 1. Target serum lithium concentrations "Target" serum lithium concentration (mmol/L) At 12 hours At 24 hours Once daily dosage 0.7 - 1.0 0.5 - 0.8 Twice daily dosage 0.5 - 0.8 4. Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available. Following stabilisation of serum lithium levels the period between subsequent estimations can be increased gradually but should not normally exceed three months. Additional measurements should be made following alteration of dosage on development of intercurrent disease signs of manic or depressive relapse following significant change in sodium or fluid intake or if signs of lithium toxicity occur. 5. Whilst a high proportion of acutely ill patients may respond within three to seven days of the commencement of LITHICARB FC therapy LITHICARB FC should be continued through any recurrence of the affective disturbance. This is important as the full prophylactic effect may not occur for 6 to 12 months after the initiation of therapy. 6. In patients who show a positive response to LITHICARB FC therapy treatment is likely to be long term. Careful clinical appraisal of the patient should be exercised throughout medication (see Precautions).Treatment of Acute Mania Hypomania and Recurrent Bipolar Depression:It is likely that a higher than normal LITHICARB FC intake may be necessary during an acute phase and divided doses would be required here. Therefore as soon as control of mania or depression is achieved the serum lithium level should be determined and it may be necessary dependent on the results to lower the dose of LITHICARB FC and re-stabilise serum lithium levels. In all other details the described treatment schedule is recommended.Prophylactic Treatment of Recurrent Affective DisordersIt is recommended that the described treatment schedule is followed.Use in the Elderly:In elderly patients or those below 50kg in weight it is recommended that the starting dose be 400mg. Elderly patients may be more sensitive to undesirable effects of lithium and may also require lower doses in order to maintain normal serum lithium levels. It follows therefore that long term patients often require a reduction in dosage over a period of years.Use in Children and AdolescentsNot recommended. Buy Intalith CR Eskalith and other Prescription Drugs 9 products online at Medstore. Buy Online at Medstore - Click Here!
About Intalith CR Eskalith: Product Type: Prescription Drugs 9 Intalith CR (Eskalith Generic Lithium Carbonate) Intalith CR (Eskalith Generic Lithium Carbonate) Eskalith Generic Lithium Carbonate 450mg 400(4 x 100) Tablets 200(2 x 100) Tablets 100 Tablets Eskalith Generic Lithium Carbonate Intalith CR
View more Prescription Drugs 9 Drugs Online: From Gulf News: Runners should avoid prescription drugs. Statins may increase production of the enzyme creatine kinase, and hence heighten chances of muscle damage in athletes. Marathon running has increased in popularity over the past three decades, with participation in the United States rising from 25,000 runners in 1976 to nearly 470,000 in 2008. Many professional and recreational runners take prescription drugs, unaware of potential side-effects that affect runners in particular. One such class of drugs, called statins, which includes medicines such as Lipitor, Crestor and Pravachol, lowers blood cholesterol by inhibiting a cholesterol-producing enzyme and may even lower the risks of heart attack and further cardiovascular disease in a narrow category of patients. A new study forthcoming in the American Journal of Cardiology examined the effect of statins on creatine kinase (CK), an enzyme linked to muscle damage. Elevated levels of CK in the blood and muscle after exercise correlates with muscle damage. The study, conducted by Dr Beth Parker of the Henry Low Heart Centre at Connecticut's Hartford Hospital, is the first to measure CK levels in athletes taking statins after physical activity in a real-life environment rather than in a university laboratory.
| ||
